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Abstract
Background
Mass anthelmintic drug administration is recommended in developing countries to address
infection by soil-transmitted helminthiases (STH). We quantified the public health benefit of
treatment with mebendazole in eight million Vietnamese children aged 5–14 years from
2006 to 2011. This was compared to the environmental impact of the pharmaceutical supply
chain of mebendazole, as the resource use and emissions associated with pharmaceutical
production can be associated with a public health burden, e.g. through emissions of fine par-
ticulate matter.
Methodology
Through Markov modelling the disability due to STH was quantified for hookworm, Ascaris
lumbricoides and Trichuris trichiura. For each worm type, four levels of intensity of infection
were included: none, light, medium and heavy. The treatment effect on patients was quanti-
fied in Disability-Adjusted Life Years (DALYs). The public health burden induced by the
pharmaceutical supply chain of mebendazole was quantified in DALYs through Life Cycle
Assessment.
Principal findings
Compared to ‘no treatment’, the modelled results of five-year treatment averted 116,587
DALYs (68% reduction) for the three worms combined and largely driven by A. lumbricoides.
The main change in DALYs occurred in the first year of treatment, after which the results sta-
bilized. The public health burden associated with the pharmaceutical supply chain was 6
DALYs.
Conclusions
The public health benefit of the Mass Drug Administration (MDA) averted substantially more
DALYs than those induced by the pharmaceutical supply chain. These results were verified
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in a sensitivity analysis. The starting prevalence for each worm was the most sensitive
model parameter. This methodology is useful for policymakers interested in a holistic
approach towards the public health performance of MDA programs, enveloping both the
treatment benefit received by the patient and the public health burden associated with the
resource consumption and environmental emissions of the pharmaceutical production and
supply chain.
Author summary
Millions of children from developing countries are infected by soil-transmitted helminthi-
ases (STH), an infection of intestinal worms that cause abdominal pain, bad absorption of
nutrients from food and a decrease in the amount of red blood cells. This disease can be
treated with anthelmintic medication, such as mebendazole, that decreases the intensity of
infection and leads to a public health benefit. Because reinfection often occurs within
months, regular treatment (every six months) is advised. Given the number of people that
are infected with this disease, numerous tablets are required each year to facilitate treat-
ment. However, the industrial production of these tablets can have a negative effect on
global human health, e.g. through emissions of fine particulate matter, which should be
considered as a public health burden. Our findings suggest that the public health benefit
of treating STH with anthelmintic medication is 18,035 times larger than the public health
burden associated with pharmaceutical production. However, the conclusion that the
health benefits for the patients outweigh the health damage due to resource use and emis-
sion from industry may not hold for every medical treatment, therefore we propose a
more holistic evaluation of health care programmes, including a broader approach
towards human health.
Introduction
Every year, millions of children from developing countries receive medicines donated through
the World Health Organization (WHO). In 2016, 1.3 billion tablets were shipped for the treat-
ment of lymphatic filariasis, soil-transmitted helminthiases (STH) and schistosomiasis [1–3].
This study focuses on STH, which comprises four nematode infections: Necator americanus,
Ancylostoma duodenale, Ascaris lumbricoides (roundworms) and Trichuris trichiura (whip-
worms). The first two are frequently combined and referred to as hookworms. In 2010, STH
affected 1.45 billion people worldwide and is associated with high morbidity due to abdominal
pain, anaemia and malabsorption of nutrients [4]. Children from the poorest developing coun-
tries are the most impacted by this disease, and 875 million children were reported to require
annual treatment in 2012 [5].
In 2012, certain pharmaceutical companies, non-governmental organizations (NGOs), gov-
ernments and banks signed the London Declaration on Neglected Tropical Diseases, commit-
ting to supply the necessary drugs to achieve control of STH by 2020 [6]. The global target is
“to eliminate morbidity due to soil-transmitted helminthiases in children by 2020, by regularly
treating at least 75% of the children in endemic areas” [7, 8]. In areas with high (>50%) preva-
lence of STH, the WHO recommends anthelmintic drug treatment every six months for
school-aged children [7]. The effect of these treatments on the prevalence of STH is reported
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in multiple studies and the global public health impact of STH has been mapped in the Global
Burden of Disease (GBD) [1, 9–12].
The pharmaceutical production, distribution and disposal of these anthelmintic drugs
requires significant resources and causes emissions of hazardous compounds, which are asso-
ciated with an effect on global human health, e.g. through emissions of fine particulate matter,
which can be seen as a public health burden and quantified through Life Cycle Assessment
(LCA) [13–15]. This environmental impact is currently not assessed along with the Mass Drug
Administration (MDA) programs. However, the WHO recognizes that environmental factors
(e.g. air pollution and Climate Change) are responsible for 22% of all global mortality and
morbidity [16]. A holistic evaluation should compare both the public health benefit of MDA
programs and the contribution to the public health burden attributable to the environment
associated with the pharmaceutical production, distribution and disposal of the medicines
[17].
The aim is to quantify and compare the public health benefit and burden for mebendazole
MDA in Vietnam by using a common metric: the Disability-Adjusted Life Year (DALY) [18].
A DALY is equivalent to one healthy life year lost. This study focuses on Vietnam, building on
a previously published model of STH prevalence progression after treatment with anthelmintic
drugs, which are supplied to Vietnam through the MDA program [9, 19]. While multiple
anthelmintic drugs are donated for the treatment of STH, data from the pharmaceutical supply
chain was only collected for mebendazole. This demonstration study aims to provide a first
insight on both the public health benefit for patients and public health burden attributable to
the environment of MDA programs.
Methods
The overall framework consists of two main parts. First, we discuss the simulation of the public
health benefit of anthelmintic treatment with mebendazole every six months. The difference in
public health morbidity associated with STH is quantified before and after the introduction of
mebendazole MDA for eight million Vietnamese children aged 5–14 years for five years,
reaching 80% coverage [20]. To do this we adopted a Markov model published by Montresor
et al. [9, 19]. The model predicts the prevalence of hookworm, A. lumbricoides and T. trichiura
on a yearly basis over a five year time horizon, which was combined with disability weights to
calculate the population morbidity on a yearly basis [4].
Second, the public health burden of the pharmaceutical supply chain of mebendazole is
quantified through an environmental LCA based on primary data. This cradle-to-grave assess-
ment includes the resource use and emissions associated with the five supply chain stages:
Active Pharmaceutical Ingredient (API) synthesis, tablet formulation, packaging, distribution
and End-of-Life. The public health burden associated with the production of the 64 million tab-
lets that are required for treatment in this study is a burden for the global population, as e.g. Cli-
mate Change is a global process. The functional unit, which is a measure of the function of the
treatment to which the environmental impact can be related, is the same as in the first part [5].
Both the public health benefit and burden associated with mebendazole MDA are expressed
in DALYs and compared to a theoretical counterfactual: the ‘no treatment’ group. This study
focuses on calculating the disability attributable only to STH infection and treatment. Any dis-
ability from other causes was out of scope.
Part I: Public health benefit of mebendazole MDA
The mebendazole MDA program, including treatment with mebendazole every six months for
five years was compared with a ‘no treatment’ group where patients were not treated and
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worm prevalence and morbidity were assumed to stay constant over time on a population
level [2].
The morbidity in the treated group was calculated on a yearly basis. The number of children
infected by each separate worm type and intensity of infection at each year were multiplied
with the disability associated with that specific infection. The prevalence and number of
infected children were able to change over time, but the disability associated with each infec-
tion state is fixed.
STH prevalence in study population. The population under study was eight million Viet-
namese children aged 5–14 that required anthelmintic treatment in 2006 [20]. This number is
assumed to stay constant over 5 years on a population level. The STH prevalence before the
introduction of MDA in 2006 (baseline prevalence) was obtained from van der Hoek et al.
(2003) that determined the total STH prevalence for each worm type in 41,799 Vietnamese
children aged 5–15 [21]. We then subdivided this into no infection, light, moderate and heavy
infection intensity according to the WHO classification listed in Table 1 and produced esti-
mated prevalence by STH type and severity shown in Table 2 [22, 23].
Markov model. A published Markov model developed to monitor MDA programs for
school-aged children was adopted to simulate the estimated reduction in STH prevalence due
to mebendazole MDA [9, 19]. The model we adopted was Transition Probability Matrix Set
(TPMS) 4 from the Supplementary Material of Montresor et al. (2016), representing the treat-
ment of 1324 school-aged children with mebendazole every 12 months (Table A in S1 Text).
The rationale for the model choice is outlined in S1 Text, page 2. As we aim to model the effect
of treatment with mebendazole every six months, as recommended by the WHO when STH
prevalence is higher than 50% and which was actually (partly) implemented in Vietnam, the
results of TPMS 4 are considered conservative [7, 20].
The model timeframe for the simulation started from the situation in Vietnam in 2006 with
a cycle length of one year and a five year time horizon, which was considered sufficiently long
to capture all health effects, since the reduction in worm burden is already visible within 14
days and mortality was not considered [25]. Over five years, it is also possible to see the effects
of reinfection, which often occurs within months [26].
The worm prevalence was calculated for each year and split up in no infection, light, mod-
erate and heavy infection intensity. This subdivision enables a detailed disability quantifica-
tion, as morbidity is highly dependent on worm burden, with heavy infection responsible for
the largest share of disability. A fourth model state was defined as ‘no infection’. This structure,
Table 1. Classes of soil-transmitted helminthiases (STH) infection based on the number of eggs per gram (epg) in a human stool sample [22].
No infection (epg) Light infection (epg) Moderate infection (epg) Heavy infection (epg)
Hookworm 0 1–1,999 2,000–3,999 �4,000
A. lumbricoides 0 1–4,999 5,000–49,999 �50,000
T. trichiura 0 1–999 1,000–9,999 �10,000
https://doi.org/10.1371/journal.pntd.0006954.t001
Table 2. Soil-transmitted helminthiases (STH) prevalence for eight million Vietnamese children subdivided in light, moderate and heavy infection before mebenda-
zole MDA [23, 24].
Total prevalence Light infection Moderate infection Heavy infection
% Pop. % Pop. % Pop. % Pop.
Hookworm 24.60 1,968,000 23.81 1,904,512 0.67 53,648 0.12 9,840
A. lumbricoides 62.60 5,007,999 37.03 2,962,632 22.59 1,807,387 2.97 237,980
T. trichiura 26.00 2,080,000 22.70 1,816,048 3.23 258,336 0.07 5,616
https://doi.org/10.1371/journal.pntd.0006954.t002
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displayed in Fig 1 for the case of hookworm, allowed patients to move throughout the four
model states each year as a result of pre-defined transition probabilities, representing treatment.
A set of transition probabilities to go from one state to another exists for each worm type.
Model disability input. The disability associated with hookworm, A. lumbricoides and T.
trichiura was estimated according to both the causes and weights of disability defined by the
Institute for Health Metrics and Evaluation (IHME) GBD reports [4, 27].
For the purposes of the model we considered the following disability causes:
• Mild abdominopelvic problems, which occur in all cases of moderate infection.
• Symptomatic infection, which occurs in all cases of heavy infection for A. lumbricoides and
T. trichiura but not for hookworm.
• Severe wasting, with country-specific prevalence, which occurs in all cases of heavy infection
for hookworm, A. lumbricoides and T. trichiura.
• Anaemia, which is further split up into mild, moderate and severe anaemia. All intensities of
anaemia are present for all intensities of hookworm infection. Anaemia is defined as a condi-
tion in which haemoglobin levels in the blood are below a certain age-dependent threshold,
listed in Table 3 [28].
We carried out two literature reviews, subdivided into four sub-analyses, with the aim to
support the assumptions regarding the disability inputs of anaemia and wasting in the model.
The search terms and results can be found in Figure A, B, C, D and E in S1 Text.
Disability due to anaemia was only considered for hookworm, because intestinal blood loss
due to STH infection is associated with this worm species [4]. Anaemia prevalence is
Fig 1. Markov model simulating the hookworm prevalence progression after each mebendazole treatment cycle of
one year, adapted from Montresor et al. 2014 and Montresor et al. 2016 [19, 23].
https://doi.org/10.1371/journal.pntd.0006954.g001
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influenced by the intensity of infection [29, 30]. The total prevalence of anaemia was subdi-
vided in mild, moderate and severe anaemia. We carried out a first literature review with the
aim to support the assumptions on both the total prevalence of anaemia associated with hook-
worm and the relative fractions of the subdivision into mild, moderate and severe anaemia
(see Figure A, B, C and E in S1 Text).
Anaemia is caused by multiple factors, and only a fraction of the disability by anaemia can
be allocated to hookworm and hence treated by deworming [31–33]. The base case percentage
of anaemia that is attributable to hookworm was estimated to be 22% [34]. Although the
assumption that deworming actually reduces the fraction of anaemia associated with hook-
worm was supported by the literature, a scenario analysis with data from multiple sources was
performed due to the lack of agreement regarding this attributable fraction (see Table 4) [30,
35, 36].
The total anaemia prevalence and the anaemia attributable to hookworm were defined as
shown in Fig 2, based on the weighted mean results of the studies detected in the literature
review [33, 34, 37–40]. The anaemia prevalence was then subdivided into relative fractions of
mild, moderate and severe anaemia: respectively 77.86%, 19.08% and 3.06% [41].
Mild and severe wasting are defined as having a weight-for-height score respectively below
-2 and -3 standard deviations from the median of a reference population [42–44]. Only severe
wasting was considered for the calculation of disability [45]. Based on input from six studies
from a second literature review, we split up the total prevalence of wasting into relative frac-
tions of mild wasting (65.75%) and severe wasting (34.25%) [46–51].
The total prevalence of wasting was obtained from the Vietnamese review of nutrition sta-
tus in 2009–2010 [52]. We adopted the wasting prevalence for children under five years of age,
which was reported as 7.1%. When multiplied with 34.25%, this results in an absolute preva-
lence of severe wasting of 2.43%. The results of the literature review can be found in Figure D
in S1 Text.
Like anaemia, wasting is also caused by multiple factors. Many families in developing coun-
tries are affected by the poverty syndrome, a vicious cycle where low income, a large family
size and poor education aggravate malnutrition over generations [53–55]. We arbitrarily
defined the percentage of wasting improvable by deworming as 50%, leading to an absolute
prevalence of severe wasting improvable by deworming of 1.22%. This was included in the sen-
sitivity analysis (relatively ±50%) and proved not to be a sensitive parameter. Our assumption
that deworming reduces wasting prevalence was supported by the literature [56–58].
The causes of disability for STH are linked to the associated disability weights from the
most recent GBD update in 2013 and are outlined in Table 5 [45].
Table 4. Scenarios on the percentage of anaemia attributable to hookworm.
Anaemia percentage attributable to hookworm Source
Scenario 1: most conservative 0.00%
Scenario 2: after introduction of MDA in Vietnam 4.12% [35]
Scenario 3: base case 22.00% [34]
https://doi.org/10.1371/journal.pntd.0006954.t004
Table 3. Anaemia thresholds based on haemoglobin level (g/l) [28].
No anaemia Mild anaemia Moderate anaemia Severe anaemia
Children 5–11 years of age 115 or higher 110–114 80–109 Lower than 80
Children 12–14 years of age 120 or higher 110–119 80–109 Lower than 80
https://doi.org/10.1371/journal.pntd.0006954.t003
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The DALYs were calculated separately for each worm type, differentiating between the
three classes of intensity, according to the following formula:
DALY ði;tÞ ¼ DW ðiÞ � pðiÞ � nði;tÞ
With DW(i) the disability weight of disability cause i, weighted by the prevalence of that cause
p(i) and multiplied with the number of children having an infection intensity susceptible for
that cause i at year t (n(i,t)) [27].
No age-weighting or discounting of disability were applied. When a person suffers from
multiple disabilities a co-morbidity adjustment was applied, e.g. in the case of moderate hook-
worm infection 100% of patients suffer from mild abdominopelvic problems while 14.54%
also suffer from different intensities of anaemia [27]. For each worm type and infection
Fig 2. Prevalence of anaemia according to intensity of infection with hookworm.
https://doi.org/10.1371/journal.pntd.0006954.g002
Table 5. Causes of disability and disability weights from the GBD 2013 associated with each intensity of STH infection [4, 45].
Cause of disability STH Intensity Prevalence improvable by deworming (%) Disability weight
Hookworm Mild anaemia All Mild hookworm: 9.25
Moderate hookworm: 11.32
Heavy hookworm: 12.62
0.004
Moderate anaemia All Mild hookworm: 2.27
Moderate hookworm: 2.77
Heavy hookworm: 3.09
0.052
Severe anaemia All Mild hookworm: 0.36
Moderate hookworm: 0.44
Heavy hookworm: 0.50
0.149
Mild abdominal problems Moderate 100.00 0.011
Severe wasting Heavy 1.22 0.128
A. lumbricoides Mild abdominal problems Moderate 100.00 0.011
Symptomatic infection Heavy 100.00 0.027
Severe wasting Heavy 1.22 0.128
T. trichiura Mild abdominal problems Moderate 100.00 0.011
Symptomatic infection Heavy 100.00 0.027
Severe wasting Heavy 1.22 0.128
https://doi.org/10.1371/journal.pntd.0006954.t005
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intensity, the average disability was calculated according to the following equation:
DW ð1þ2Þ ¼ 1   ð1   DW ð1ÞÞ � ð1   DW ð2ÞÞ
Assumptions and limitations. The prevalence of wasting was based on children under
five years of age, who are the most vulnerable group. On the one hand, this might have been
an overestimation because children aged 5–14 are less vulnerable to wasting. On the other
hand, this might have been an underestimation because the wasting prevalence for individuals
who are heavily infected with STH was now based on a sample from the general population,
which diluted the effect. This was tested in the sensitivity analysis. The model calculations
assumed an instantaneous recovery of disability when children were free of infection, while in
practice this might take longer. There was a possibility of double counting when a person was
infected by multiple worms. In that case the disability of wasting, symptomatic infection or
abdominopelvic problems could have been counted multiple times, which is a limitation of the
non-individualised cohort state-transition Markov model type [59]. A reduction of mortality
associated with STH after deworming was not taken into account, which was considered a
conservative approach [56, 58, 60]. We did not account for mental disability such as reduced
cognitive development and school performance of children. We also did not consider the
influence of initiatives other than deworming, such as Water, Sanitation and Hygiene
(WASH) programs. The variation in coverage of anthelmintic treatment in Vietnam over the
years was not taken into account in this simulation. We assumed a constant coverage of 80%,
which is the same as the coverage that was reached in the program on which the Markov
model (TPMS 4) was based (A. Montresor, personal communication).
Part II: Public health burden
The public health burden of mebendazole Mass Drug Administration (MDA) was analysed
through Life Cycle Assessment (LCA) methodology, which considered the full cradle-to-grave
impact of the pharmaceutical supply chain. The resource use and emissions associated with
the production of the medicine are linked to environmental cause-effect chains, enabling the
quantification of the environmental impact [61–63]. For example, burning natural gas leads to
an emission of CO2 (kg), which is associated with a radiative forcing in the atmosphere (W/
m2), causing a global mean temperature increase (˚C). The latter may lead to disability through
direct effects of (extreme) heat or cold, foodborne and waterborne diseases, vector-borne dis-
eases, natural disasters and risk of malnutrition [64, 65]. In this study we focus on the environ-
mental impact which causes a global Human Health burden [17, 66].
Applied functional unit. The applied functional unit was the treatment with mebenda-
zole 500 mg tablets every six months for five years of eight million children in Vietnam, aged
5–14, reaching 80% coverage [9]. In total 64 million tablets were required for this.
Goal and scope of the LCA. The study aimed to quantify the public health burden in Dis-
ability-Adjusted Life Years (DALY) associated with the pharmaceutical supply chain of
mebendazole. The scope included the chemical synthesis of the Active Pharmaceutical Ingredi-
ent (API), tablet formulation, packaging, distribution and End-of-Life disposal. Resource use
and emissions associated with health care utilization outside of the MDA program, e.g. hospi-
talization, was not taken into account.
Methods. The data were collected, processed and results provided according to the ISO
14040 and ISO 14044 standards and International Reference Life Cycle Data System (ILCD)
guidelines [62, 63, 67, 68]. One exception was made regarding the use of Endpoint methods
for the reporting of results.
Public Health benefit and burden of mebendazole MDA in Vietnam
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006954 November 12, 2018 8 / 22
Life cycle inventory. To feed the model, the inventory of the pharmaceutical supply chain
was gathered from Janssen Pharmaceutica, and their external supply partners where primary
data were necessary. The system boundaries were the limits of the production plants, however
transport of intermediate products between plants was included, as well as the final transport
to the children in Vietnam. We included the industrial unit operations as well as the plant sup-
porting processes. We used primary data and the electricity mix was adapted concerning the
origin of the electricity generation per production site.
The ecoinvent v3.1 database provided background data for the basic resources, e.g. energy
and chemicals, entering the production system and waste treatment, extracted through Sima-
Pro v8 software.
For the API synthesis, both data from the older production process of Janssen Pharmaceutica
as from the current external supplier were used. Original Batch Production Records (BPRs) from
the older process served as an input for the shortcut LCA Tool developed by Van der Vorst et al.
[69], which were then updated with current process yields, provided by the external supplier. The
resource use and associated emissions of the Heating, Ventilation and Air Conditioning (HVAC)
system, not included in the shortcut LCA Tool, were collected from the external supplier.
Data for the tablet formulation and packaging was retrieved from Batch Production
Reports, Cleaning Procedures, Equipment Manuals, MSDS files, yearly planning and P&ID’s
from the external supplier. The indirect resource use of supporting processes such as HVAC,
heating, cooling, generation of purified water and steam was included, together with waste
treatment operations.
The distribution included the transport by truck and barge from the external supplier to
Hanoi (Vietnam). From there we included car transport to distribute the mebendazole tablets
to province and district level (D. Do Trung, personal communication). Distribution on com-
munity level was not included.
The End-of-Life phase considered the landfilling of the packaging waste, although in prac-
tice the empty bottles are frequently reused by the local population. The End-of-Life toxicity of
mebendazole in continental freshwater was based on Environmental Risk Assessment (ERA)
data such as the Bio Concentration Factor (BCF) and EC50 values. We excluded the fraction of
API metabolised in the patient (10%) and assumed no removal by Wastewater Treatment after
excretion by the patient (Janssen Pharmaceutica, personal communication).
Life cycle impact assessment. The ReCiPe v1.11 impact assessment method was used to
quantify the public health burden induced by six environmental cause-effect chains: Climate
Change, Human Toxicity, Ionizing Radiation, Ozone Depletion, Particulate Matter Formation
and Photochemical Oxidant Formation [65, 66, 70, 71]. The hierarchical perspective was cho-
sen [72–74].
The End-of-Life impact of the molecule was calculated through USEtox [63, 75, 76]. Using
data from the ERA documents, USEtox applies a cause-effect chain that quantifies the number
of disease cases associated with the mass (kg) of mebendazole released into the wastewater,
based on fate, exposure and effect factors. As mebendazole is not a carcinogen, the average
DALYs associated with non-cancer diseases (2.7) is applied per disease case [71].
The results of the LCA were divided according to the following direct inputs of the pharma-
ceutical supply chain: water, nitrogen, chemicals (reagents and solvents), energy (natural gas,
electricity), packaging materials, industrial waste treatment, transport (pharmaceutical supply
chain, distribution) and End-of-Life toxicity. Industrial waste treatment concerned the treat-
ment of waste from production sites, whereas End-of-Life toxicity represented impact from
post-consumer waste.
Assumptions and limitations. We considered only the pharmaceutical supply chain of
mebendazole as a source of public health burden. This implies that no other health care
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utilization, e.g. hospitalization, was considered for its public health burden originating from
resource use and emissions. Returns and destructions of medication were not assessed.
Results
The modelled public health outcomes of five years mebendazole MDA compared to the base-
line are listed in Table 6. The DALYs for the A. lumbricoides and T. trichiura treatment groups
decreased over five years, while the DALYs of the hookworm treatment group increased and
the DALYs of the ‘no treatment’ group stayed constant over time. This way mebendazole
MDA averted 119,088 DALYs (89.32% reduction) for A. lumbricoides and 10,575 DALYs
(70.46% reduction) for T. trichiura compared to the ‘no treatment’ group. For hookworm,
there was an increase in DALYs of 13,076 (55.02% increase), which is a counterintuitive result
as mebendazole is known to have efficacy against hookworm in terms of egg reduction rate,
and thus morbidity [25, 77–79]. In total 116,587 DALYs are averted for the three worms com-
bined, which is a reduction of 67.74%. The treatment effect was the most pronounced in the
first year. After an initial drop in disability the values stabilized over time because an equilib-
rium with reinfection was reached [26].
Fig 3 and Fig 4 provide more detail and display respectively the STH prevalence and
DALYs attributable to both intensity of infection and cause of disability over five years of
mebendazole MDA. Fig 3 shows that compared to the initial baseline values before treatment,
the total prevalence absolutely decreased with 8.61% for hookworm, 56.18% for A. lumbri-
coides and 21.04% for T. trichiura. The prevalence of heavy infection in all three worms
reached 0% after one year of treatment.
Table 6. Disability-Adjusted Life Years (DALYs) after the introduction of mebendazole MDA for eight million Vietnamese children. The ‘no treatment’ group has
DALY values equal to the baseline for each year.
hookworm A. lumbricoides T. trichiura
DALYs after
MDA
DALYs averted per
year
DALYs after
MDA
DALYs averted per
year
DALYs after
MDA
DALYs averted per
year
Total cumulative DALYs
averted
Baseline 4,754 26,667 3,002
Year 1 6,861 -2,108 4,236 22,431 884 2,118 22,440
Year 2 7,433 -2,679 2,811 23,856 888 2,114 45,731
Year 3 7,514 -2,761 2,464 24,202 888 2,114 69,287
Year 4 7,518 -2,765 2,378 24,289 888 2,114 92,925
Year 5 7,517 -2,763 2,356 24,311 888 2,114 116,587
Total -13,076 119,088 10,575 116,587
https://doi.org/10.1371/journal.pntd.0006954.t006
Fig 3. Soil-transmitted helminthiases (STH) prevalence over five years of mebendazole Mass Drug Administration (MDA) for eight million Vietnamese children.
https://doi.org/10.1371/journal.pntd.0006954.g003
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From the top part of Fig 4 it is notable that for A. lumbricoides and T. trichiura all DALYs
are attributable to moderate and heavy infection at baseline, while after the first year of treat-
ment all DALYs are attributable to moderate infection. For hookworm light infection is
responsible for 83.79% of disability at baseline, while for later treatment years light infection
and moderate infection are each responsible for around 25% and 75% of the DALYs, respec-
tively. These trends can also be seen in the bottom part of Fig 4, where the DALYs attributable
to mild abdominopelvic problems and symptomatic infection correspond with the public
health burden of respectively moderate and heavy infection. For hookworm however, the larg-
est share of DALYs at baseline can be attributed to anaemia, while after the first year of treat-
ment mild abdominopelvic problems are responsible for the largest amount of DALYs.
At year 5, the fractions of DALYs averted from moderate infection compared to baseline
were 88.15% and 68.77% for A. lumbricoides and T. trichiura, respectively. For hookworm, the
DALYs from moderate infection increased with 687.2%. After the first year of treatment, 100%
of the DALYs due to heavy infection are averted for all three worms.
The results of the scenario analysis on the percentage of anaemia attributable to hookworm
are displayed in Table 7. In the most conservative scenario where 0% of anaemia is attributable
to hookworm, the DALYs due to hookworm increased with 19,726 (negative DALYs averted)
over five years of mebendazole MDA.
The public health burden associated with the pharmaceutical supply chain is provided in
Table 8. A public health burden of 6.46 DALYs was caused by the production, distribution and
disposal of 64 million mebendazole tablets. API synthesis represented the largest impact
(86.41%) with electricity and chemical reagents as the main drivers. Formulation of the tablets
was responsible for the second largest impact, mainly due to electricity use. A table with results
on midpoint impact categories can be found in Table E in S1 Text.
Fig 4. Soil-transmitted helminthiases (STH) DALYs attributable to both intensity of infection and cause of disability over five years of mebendazole Mass Drug
Administration (MDA) for eight million Vietnamese children.
https://doi.org/10.1371/journal.pntd.0006954.g004
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When comparing the public health benefit to the burden, even when including the theoreti-
cal increase in DALYs from hookworm infection, 18,035 times more DALYs were averted
than created.
A one-way and probabilistic sensitivity analysis were carried out, to be found in Table F
and Figure F, G, H and I in S1 Text. The conclusion did not change; in all cases the public
health benefit because of mebendazole Mass Drug Administration was larger than the public
health burden associated with the pharmaceutical supply chain. The starting prevalence for
each worm was the most sensitive model parameter.
Discussion
Statement of principal findings
The treatment of eight million Vietnamese children with mebendazole for five years substan-
tially decreased STH prevalence and averted 116,587 DALYs for the children compared to a
‘no treatment’ group, which is a reduction of 67,74%. To do this, 64 million mebendazole tab-
lets are required, creating 6.46 DALYs associated with the pharmaceutical supply chain. A fac-
tor 18,035 more DALYs were averted than created. The increase in DALYs from hookworm
infection is considered a counterintuitive result.
Strengths and weaknesses of the study
This is one of the first attempts to compare the public health benefit of health care MDA pro-
grams to the public health burden associated with resource use and emissions of the pharma-
ceutical supply chain, using a common metric.
Table 8. Disability-Adjusted Life Years associated with the pharmaceutical supply chain of five years mebendazole MDA (64 million tablets).
API Synthesis Formulation Packaging Distribution End-of-Life Total
Water 0.002 0.000 0.000 - - 0.002
Nitrogen 0.124 0.000 0.000 - - 0.124
Chemicals—Reagents 1.846 0.033 0.000 - - 1.880
Chemicals—Solvents 0.996 0.001 0.000 - - 0.997
Energy—Natural Gas 0.058 0.002 0.000 - - 0.060
Energy—Electricity 2.488 0.709 0.011 - - 3.208
Packaging materials 0.000 0.000 0.042 - - 0.042
Industrial Waste Treatment 0.036 0.012 0.000 - - 0.049
Transport—pharmaceutical supply chain 0.036 0.000 0.000 - - 0.100
Transport—distribution to Vietnam - - - 0.064 - 0.004
EOL Toxicity - - - - 0.004 0.004
Total 5.586 0.757 0.053 0.064 0.004 6.465
86.41% 11.72% 0.82% 0.99% 0.06%
https://doi.org/10.1371/journal.pntd.0006954.t008
Table 7. Scenarios on the percentage of anaemia attributable to hookworm.
Anaemia percentage attributable to
hookworm
DALY averted for
hookworm
Scenario 1: most conservative 0.00% -19,726
Scenario 2: after introduction of MDA in
Vietnam
4.12% -18,481
Scenario 3: base case 22.00% -13,076
https://doi.org/10.1371/journal.pntd.0006954.t007
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From an LCA perspective, there is a growing interest to quantify the benefit or handprint of
products, rather than focus only on the environmental burdens [80, 81]. Simultaneously there
is a willingness to include environmental assessments in health care decision making. A recent
survey indicates that 71% of health care decision makers think the criteria of environmental
impact should be considered when making decisions on health care interventions [82]. These
developments suggest that there is support for a more holistic approach of health care inter-
ventions, which we aimed for in this study.
We aimed towards a transparent calculation of DALYs, using a previously published Mar-
kov model. The model was then linked with literature on the disability associated with STH.
The cradle-to-grave scope of the Life Cycle Assessment included the full pharmaceutical
supply chain. The public health burden was based on multiple primary data sources. This
holistic approach, combining different fields of research, could allow program managers to
estimate the net public health performance of MDA programs.
The following limitations of the study should be noted. The modelling approach that was
taken in this study was based on imperfect information. We aimed to provide the data inputs
for the model through literature review, but given the paucity of certain data regarding STH
some inputs were adopted from sources or settings that differ from the one in this study. For
example, the Markov model transition probabilities were based on a study in Pemba island,
Tanzania, instead of Vietnam. A full overview of model inputs, assumptions and limitations
can be found in Table B, C and D in S1 Text.
The transition probabilities of the Markov model adopted in this study cause the prevalence
of light, moderate and heavy infection to reach steady state values over five years treatment,
regardless of the initial setting, i.e. starting prevalence [83]. In the case of moderate hookworm
infection the starting prevalence (0.67%) is lower than the steady state prevalence (5.28%),
causing a theoretical increase in both prevalence and DALYs, rather than a decrease. We con-
sider this a counterintuitive result and the main limitation of the Markov model: it reports a
decrease in health status, rather than an increase, when the starting prevalence is lower than
the steady state value reached over time.
The relatively high steady state value after treatment for moderate hookworm may have
been influenced by the high untreated hookworm prevalence in the population on which the
TPMS 4 transition probabilities were based. In that study, the initial prevalence of moderate
hookworm was 20.02%, with a total hookworm prevalence of 70.02% in 1324 children, which
is 45.42% higher than the total hookworm prevalence in this study (A. Montresor, personal
communication). These findings were also confirmed in a 1994 study in 3595 children from
the same Pemba island, Tanzania, which reported moderate hookworm infection at 13.30%,
with a total hookworm prevalence of 93.73% [37]. For A. lumbricoides and T. trichiura the ini-
tial prevalence in the population on which the model was based was 75.00 and 26.96%, respec-
tively. These values are respectively 12.40 and 0.96% higher than the initial prevalence from
Vietnam used in this study. It should also be noted that the source for STH prevalence in this
study is an average of multiple provinces in Vietnam, which ignores the high variability across
regions.
From the one-way and probabilistic sensitivity analysis in S1 Text it can be seen that a 50%
relative change in starting prevalence can have a marked influence on the results. A what-if
analysis showed that, all other values held constant, increasing the starting prevalence of mod-
erate hookworm from 0.67% to 3.15% causes the total DALYs averted for hookworm to
become 0. Further increasing said starting prevalence leads to positive DALYs averted. If the
initial untreated prevalence is lower than the steady state values, it could be argued to keep the
values constant from a model perspective, rather than let them increase. However, for the sake
of transparency, we did not adapt the model. Another peculiar part of the transition matrix is
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PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006954 November 12, 2018 13 / 22
the fact that for all three worms the probability of going from heavy infection to no infection is
1, instead of the more gradual decrease from heavy to moderate and then light infection that
could be expected.
Aside from model considerations, the efficacy of mebendazole to treat hookworm has been
reported as highly variable by Keiser et al. (2008) and more recently by Moser et al. (2017). As
a result, combining hookworm data from different sources can possibly lead to higher preva-
lence after treatment compared to the baseline. Considering the limitations of the model, the
results for hookworm are unlikely and should be conservatively interpreted.
The counterintuitive result for hookworm may lead to certain skepticism regarding the
results for A. lumbricoides and T. trichiura. In this case, the cause for said counterintuitive
result is a methodological weakness of the Markov model concept. The transition probabilities
of a Markov model that predicts a treatment effect are always influenced by the pre-treatment
situation, in this case the prevalence. The Markov model we used in this study was based on
children in Tanzania, and while the starting prevalence for A. lumbricoides and T. trichiura in
Vietnam were in line with the values from Tanzania, as discussed earlier, those for hookworm
were not. Therefore the results for hookworm should be interpreted conservatively, but that
does not follow for A. lumbricoides and T. trichiura.
We applied a static transmission model (constant probabilities), which has limitations com-
pared to dynamic transmission modelling when considering communicable diseases [84].
While the linear transition probabilities in the Markov model allowed the prevalence of STH
to reach a steady state value after year 2, MDA may actually lead to a complete elimination of
the disease, which could be captured with the non-linear structure of a dynamic transmission
model. Dynamic models may also include the indirect effects of treatment that arise from
averted infections: while this study focuses on the treatment of children aged 5–14, it is possi-
ble that as a result younger children or adults have a reduced risk of infection because a lower
fraction of the population is infected. Because of that, our results may be an underestimation
of the treatment effect. Considering the specific case of comparing the public health benefit
and burden of MDA programs, our findings clearly indicate that the benefit outweighs the
burden. In that regard, applying a dynamic model may not be necessary [84]. An exception is
probably the specific case of hookworm, where the quantification of DALYs over time may
have benefited from a dynamic transmission model.
We aimed to use data from populations of Vietnamese children as much as possible. How-
ever, available published data was limited and in particular for the transition probabilities and
assumptions regarding the prevalence of anaemia, data input originated from studies outside
Vietnam: Brazil, Tanzania, Zimbabwe and Malaysia. There exist significant regional differ-
ences in the prevalence of anaemia, and although a general trend was observed across studies,
Vietnamese data could have increased the validity of the outcomes.
The Life Cycle Assessment excluded any health care related resource use or emissions out-
side the pharmaceutical supply chain, e.g. the treatment of any co-morbidities in hospitals.
Mebendazole MDA might increase the overall health of children, reducing the need for hospi-
talization and its associated resource use. However, the direct link between STH infection and
hospitalization is not clear. This potential consequential reduction in environmental impact
was not taken into account, which is considered conservative. There is a real possibility that a
fraction of the tablets are lost before administration to the children in Vietnam (Janssen Phar-
maceutica, personal communication). These losses were not taken into account, but would
probably not have changed the main conclusions. Multiple anthelmintic drugs are donated for
the treatment of STH, but data from the pharmaceutical supply chain was only collected for
mebendazole. Because of that, other anthelmintic drugs such as Albendazole were not consid-
ered in this simulation.
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In Life Cycle Impact Assessment multiple methods exist [63]. We adopted the grouping of
environmental midpoint (effect) categories to calculate results on endpoint (damage) given the
opportunity to directly compare the public health benefit and burden of MDA programs [85].
Strengths and weaknesses in relation to other studies
A recent study by Montresor et al. quantified the DALYs that were averted from 2010 to 2015
by anthelmintic treatment, compared to the baseline morbidity present in 2010 due to the lack
of large-scale treatment [86]. Similar to this study, the calculation of the averted DALYs is also
based on the reduction in STH prevalence after treatment. The varying national coverage over
the years was taken into account, contrary to the assumption in this study that the coverage
remains constant. However, a more linear approach is used, linking the reduction in prevalence
to a reduced morbidity through the elimination of cases of moderate and heavy intensity of
infection, as defined by Marocco et al. [87]. The averted DALYs are quantified from a top-down
approach adopting data from the WHO, rather than quantifying them separately for each inten-
sity of infection [88]. The estimated fraction of averted DALYs for children aged 5–14 in the
South East Asia Region is 64%, including widely varying treatment coverages. For the same age
group and region, Montresor et al. estimate that 84% of DALYs could be averted by 2020 if 75%
coverage is reached. The estimations in our study are more conservative and are more in line
with the general South East Asia Region. The fact that hookworm theoretically increases
DALYs instead of averting them in this study adds to the conservative nature of our estimate.
We compared the estimated DALYs from the Global Burden of Disease (GBD) report due
to STH in Vietnam for children aged 5–14 with the results of this study. Although it is unclear
to which degree the baseline STH prevalence in Vietnam of the GBD study compares to that of
our study, the results from the GBD in 2005 and 2010 are generally consistent with our Mar-
kov simulation from 2006 to 2011 for A. lumbricoides and T. trichiura. For hookworm the
large decrease in DALYs from the GBD is not visible in our study, as discussed earlier.
We identified one prior study that reports both patient outcomes and environmental
impact for an, albeit different, pharmaceutical treatment [89]. However, as patient benefit and
environmental burden are reported in two different metrics, the results of that study are not
directly comparable to the outcomes of this study.
The literature retrieved in this study supports the claim that hookworm infection was asso-
ciated with higher anaemia prevalence. We assumed the anaemia prevalence would then
decrease with deworming. However, this was not confirmed by all reviews identified in the lit-
erature. While Gulani et al. and Smith et al. report increased haemoglobin after deworming,
Hall et al. reported no effect. Taylor-Robinson et al., state that there was insufficient evidence
to know whether deworming effects haemoglobin, although their approach diverges from the
other reviews in that mainly the effect of MDA on an unscreened population was quantified.
Due to the high number of individuals that are either not infected or have a light infection, the
treatment effect on the smaller fraction of moderate and heavily infected individuals may have
been diluted [30, 36, 57, 58, 90–92]. As shown in the scenario analysis, the conclusion of the
study holds even with no reduction of anaemia prevalence due to treatment.
For wasting there is more agreement that deworming increases weight and height, support-
ing the assumptions of this study. Hall et al. state that deworming leads to significant extra
gains in weight and height if STH prevalence is above 50% [90]. Taylor-Robinson et al. report
that treating infected children with a single deworming dose may increase weight gain over the
next six months [57]. While Welch et al. note little to no improvement on weight or height 12
months after mass deworming, a subgroup analysis on children with STH prevalence >20%
does suggest weight gain [56].
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Implications of the study
The results of this study suggest that MDA of mebendazole for the treatment of STH substan-
tially averts disability, based on limited evidence for children aged 5–14 in Vietnam, even if the
public health burden of the pharmaceutical supply chain is fully considered. The public health
burden associated with the pharmaceutical supply chain of mebendazole is negligible when
compared to the public health benefit and expressed in a common metric.
This methodology may be useful if future policy would place a heavy emphasis on environ-
mental considerations. For example, we could consider a future where the effectiveness of the
treatment would not only be compared to the monetary costs (cost-effectiveness) but also to
the environmental impact. Furthermore, consider a scenario where the limiting factor of the
total national health care budget is accompanied with a limited total environmental impact e.g.
through managed decline of emissions [93]. Next to cost-effectiveness, this would require a
framework to simultaneously evaluate the environmental burden and the effectiveness of phar-
maceutical treatments. We aimed to propose such a framework in the current study.
Unanswered questions and future research
The main limitation of this study is related to the transition probabilities of the Markov model,
which reach a steady state value after several years of treatment, allowing DALYs to increase if
the initial prevalence is below the steady state value, as is the case with hookworm. While the
Markov model has advantages with respect to transparency and reproducibility, the latter issue
could be addressed in future research by developing transition probabilities that adapt to the
starting prevalence. A future study with a singular focus on the treatment benefit over time
(and not including the burden through Life Cycle Assessment) may apply a dynamic transmis-
sion model to address the same previously mentioned issue. Quantitative evidence on the
long-term influence of STH infection on developmental and cognitive abilities is required to
include this disability in future models. The influence of treatment of co-morbidities, both for
the patient and the environment, should be included to capture the broader public health
impact of STH infection. The influence of Water, Sanitation and Hygiene (WASH) programs
on the health of children infected with STH could be included in future studies next to
deworming. Health care utilization other than deworming, e.g. hospitalization, could be
included if there is a clear link with STH infection.
The results of this study and their generalizability should be validated with research on
other disease areas, countries, health care settings and standards. The environmental part of
this study is limited to impacts on public health. Other environmental Areas of Protection
(AoP), such as depletion of natural resources and damage to ecosystems may be considered for
inclusion in future studies to capture all environmental aspects.
We considered the specific case of mebendazole, and many challenges still remain to cap-
ture the full impact of STH infection. However, this study provides a first insight on the public
health benefit and burden of MDA programs, evaluated with a holistic approach that includes
both the treatment benefit for the patient and the public health burden induced by the phar-
maceutical supply chain. Such a methodology might be useful for policymakers interested in a
holistic approach towards the two scientific fields that are described.
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